Vista Labs Shines in Q1 FY27: Income Up 13.7% to ₹1,129 Mn, PAT at ₹210 Mn
Hyderabad-based Vimta Labs Limited, a leading Contract Research and Testing Organization (CRTO), has reported a healthy financial performance for the quarter ended June 30, 2026. The company announced its unaudited Q1 FY27 financial results on July 20, 2026, delivering double-digit growth in revenue, EBITDA, and profit despite ongoing global market uncertainties.
The performance was supported by strong demand for pharmaceutical research and testing services, while the company continued investing in new capabilities to drive long-term growth.
Vimta Labs Q1 FY27 Financial Highlights
The company recorded steady year-on-year growth across key financial metrics.
| Particulars | Q1 FY27 | Q1 FY26 | YoY Growth |
|---|---|---|---|
| Total Income | ₹1,129 million (₹112.9 crore) | ₹993 million* | 13.7% |
| EBITDA | ₹411 million | ₹354 million* | 16.0% |
| EBITDA Margin | 36.4% | 35.7%* | Improved |
| Profit After Tax (PAT) | ₹210 million | ₹188 million* | 11.4% |
| PAT Margin | 18.6% | — | — |
| Basic EPS | ₹4.70 | ₹4.20 | 11.0% |
*Approximate prior-year figures are derived from the reported growth percentages.
The results demonstrate the company’s ability to maintain strong profitability while expanding its service offerings.
Pharmaceutical Research Drives Growth
According to the management, the Pharmaceutical Research and Testing Services segment remained the primary growth driver during the quarter.
Demand for research, analytical testing, and regulatory services continued to support revenue growth, highlighting the resilience of the company’s diversified business model.
Food Testing Business Faces Global Headwinds
While pharmaceutical services performed well, the Food Testing division continued to experience pressure due to ongoing global economic uncertainties.
However, management indicated that the impact was partially offset through:
- Increased domestic business.
- Improved local market penetration.
- Diversification of customer segments.
- Expansion of service offerings.
The company remains focused on strengthening its position in the domestic testing market.
Operational Milestones
Vimta Labs achieved several important operational milestones during the quarter.
Successful Ukraine Regulatory Audit
The company successfully completed a regulatory audit conducted by Ukrainian authorities, reaffirming its commitment to:
- Quality assurance.
- Regulatory compliance.
- International standards.
- Scientific excellence.
The successful audit further strengthens Vimta’s credibility among global pharmaceutical clients.
Expansion into Biologics Contract Research
The company also commenced operations in Biologics Contract Research and Development Services, expanding its capabilities in one of the fastest-growing segments of the pharmaceutical industry.
The new service line is expected to:
- Diversify revenue streams.
- Expand the customer base.
- Strengthen scientific capabilities.
- Capture emerging opportunities in biologics research.
Management Commentary
Managing Director Dr. S. P. Vasireddi highlighted that the company’s performance reflects the strength of its diversified operating model.
Management acknowledged the challenges affecting the Food Testing business but expressed confidence that strong growth in pharmaceutical research services, combined with deeper domestic market penetration, would continue supporting overall business performance.